<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Problems of Virology</journal-id><journal-title-group><journal-title xml:lang="en">Problems of Virology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы вирусологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0507-4088</issn><issn publication-format="electronic">2411-2097</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">12251</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Estimation of the commercial elisa test-systems of different formats to detect specific igM and igG in the measles patients sera</article-title><trans-title-group xml:lang="ru"><trans-title>Оценка коммерческих тест-систем ИФА разного формата для определения уровня специфических IgM и IgG в сыворотках больных корью</trans-title></trans-title-group></title-group><pub-date date-type="pub" iso-8601-date="2013-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2013</year></pub-date><volume>58</volume><issue>5</issue><issue-title xml:lang="en">VOL 58, NO5 (2013)</issue-title><issue-title xml:lang="ru">ТОМ 58, №5 (2013)</issue-title><fpage>43</fpage><lpage>48</lpage><history><date date-type="received" iso-8601-date="2023-06-09"><day>09</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Mamaeva T.A., Naumova M.A., Zheleznova N.V., Lipskaya G.Y., Mulders M., Featherstone D.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, Мамаева Т.А., Наумова М.А., Железнова Н.В., Липская Г.Ю., Mulders M., Featherstone D.A.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Mamaeva T.A., Naumova M.A., Zheleznova N.V., Lipskaya G.Y., Mulders M., Featherstone D.A.</copyright-holder><copyright-holder xml:lang="ru">Мамаева Т.А., Наумова М.А., Железнова Н.В., Липская Г.Ю., Mulders M., Featherstone D.A.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://virusjour.crie.ru/jour/article/view/12251">https://virusjour.crie.ru/jour/article/view/12251</self-uri><abstract xml:lang="en"><p>Nine commercial kits of "captured" and "indirect" format ELISA assay for the detection of specific IgM and IgG in sera of patients with measles were compared to each other. 72 sera specimens from typical medium-severity cases from a measles outbreak (2010) were collected on the 5-6th day after the rash onset. Igm was detected with "capture" tests (Vecto-measles Igm, Vector Best, measles Igm capture EIA, microimmune ltd) close to 100% of cases, irrespectively to the age and the initial vaccination status of the patients. The Igm result was negative in 23.6% by average while investigating using "indirect" format tests (Enzygnost® anti-measles Virus/igm, siemens; anti-measles Viruses ELIsA (^M), Eurominimum, Virion-serion Igm (GmbH). these cases were in adults, the majority of which had 1-2 vaccinations in the past. the analysis of the presented data shows high correlation connection between the tests used and high confidence level for oD Igm and IgG of the sera of the patients with the primary and secondary immune response.</p></abstract><trans-abstract xml:lang="ru"><p>Оценены чувствительность и оперативные характеристики девяти коммерческих тест-систем (иммуно-ферментный анализ - ИФА) для определения уровня специфических igM и igG разного формата: indirect и capture. Материалом исследования стали 72 сыворотки больных типичной среднетяжелой формой кори из очага инфекции (2010), полученные на 5-6-е сутки после появления сыпи. Установлено, что с помощью тестов формата capture (VectoMeasles igM, Vector-Best; Measles igM capture EiA, Microimmune Ltd) igM определялись практически в 100% случаев независимо от возраста и исходного вакцинального статуса больного, тогда как при использовании тестов формата indirect (igEnzygnost® Anti-Measles Virus/igM Siemens, Anti-Measles Viruses ELiSA igM) Euroimmun, Virion-Serion igM GmbH) результат был отрицательным в среднем у 23,6% взрослых, большинство которых имели 1-2 прививки в прошлом. Достоверность анализа показателей OD igM и igG, полученных при исследовании сывороток у больных с первичным и вторичным иммунным ответом разными тестами, высокая и не зависит от формата изученных тест-систем, о чем свидетельствуют значения F-критерия.</p></trans-abstract><kwd-group xml:lang="en"><kwd>measles</kwd><kwd>specific antibodies</kwd><kwd>immunity</kwd><kwd>test-systems</kwd><kwd>ELISA method</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>корь</kwd><kwd>специфические антитела</kwd><kwd>иммунитет</kwd><kwd>тест-системы</kwd><kwd>ИФА-метод</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Зверев В.В., Маркушин С.Г., Юминова Н.В. Корь. СПб.: Санкт-Петербургский универсистет; 2004</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Тихонова Н.Т., Алешкин В.А., Герасимова А.Г., Мамаева Т.А., Лазикова Г.Ф. Теоретические и практические аспекты элиминации кори в России. В кн.: Теоретические и практические аспекты элиминации кори в России. М.: ФБУН "МНИИЭМ им. Г.Н. Габричевского"; 2005: 14-8</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bellini W. J., Rota P. A. Biological feasibility of measles eradication. Virus Res. 2011; 162 (1-2): 72-9.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Muller C.P. Measles elimination: old and new challenges? Vaccine. 2001; 19 (17-19): 2258-61.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Strebel P.M., Cochi S.L., Hoekstra E., Pota P.A., Featherstone D., Bellini W.J., Katz S.L. A World without measles. J. Infect. Dis. 2011; 204: 1-3.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Мамаева Т.А., Тихонова Н.Т., Наумова М.А., Шульга С.В. Национальная лабораторная сеть Российской Федерации по диагностике кори и ее роль в выполнении программы ВОЗ по ликвидации кори. Здоровье населения и среда обитания. 2007; 11 (176): 4-7</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Featherstone D.A., Rota P.A., Icenogle J., Mulders M.N., Jee Y., Ahmed H. Expansion of the global measles and rubella laboratory network 2005-09. J. Infect. Dis. 2011; 204 (suppl. 1): S 491-8.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Onishchenko G.G., Ezhlova E.B., Gerasimova A.A., Tsvirkun O.V., Shulga S.V, Lipskaya G.Y. et al. Progress toward measles elimination in the Russian Federation, 2003-2009. J. Infect. Dis. 2011; 204: 366-72.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Shulga S.V, Rota P.A., Kremer J.R., Naumova M.A., Muller C.P., Tikhonova N.T. et al. Genetic variability of wild-type measles viruses, circulating in the Russian Federation during the implementation of the National Measles Elimination Program, 2003-2007. Clin. Microbiol. Infect. 2009; 15 (6): 528-37.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Tikhonova N.T., Bichurina M.A., Gerasimova A.G., Zvirkun O.V., Vladimirova N.P., Mamaeva T.A. et al. Enhanced surveillance for measles in low-icidence territories of the Russian Federation: defining a rate for suspected case investigation. Epidemiol. Infect. 2011. 139: 239-46.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Manual for the laboratory diagnosis of measles and rubella virus infection. Geneva, Switzerland. WHO; 2006.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Arista S., Ferraro D., Cascio A., Vizzi E., di Stefano R. Detection of IgM antibodies specific for measles virus by capture and indirect enzyme immunoassays. Res. Virol. 1995; 146 (3): 225-32.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Hickman C.J., Hyde T.B., Sovers S.B., Mercader S., McGrew M., Williams N.G. et al. Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated Individuals. J. Infect. Dis. 2011; 204 (l1): 549-58.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ratnam S., Tipples G., Head C., Fauvel M., Fearon M., Ward B.J. Perfomance of indirect immunoglobulin M (IgM) serology test and IgM capture assays for laboratory diagnosis of measles. J. Clin. Microbiol. 2000; 38: 99-104.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Rota J.S., Hickman C.J., Sovers S.B., Pota P.A., Mercader S., Bellini W.J. Two case studies of modified measles in vaccinated physicians exposed to primary measles case: high risk of infection but low risk of transmission. J. Infect. Dis. 2011; 204: 559-63.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Rossier E., Miller H., McCuloch B., Sullivan L., Ward K. Comparison of immunofluorescence and enzimoimmunoassey for detection of measles-spesific immunoglobulin M antibody. J. Med. Virol.1991; 29: 1069-71.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bang H., Davidjan M. Experimental statistics for biological sciences. Methods Mol. Biol. 2010; 620: 3-104.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Meдик В.А., Toкмачев M.С., Фишман Б.Б. В кн.: Koмаров Ю.M., ред. Статистика в медицине и биологии. Tеоретическая статистика. М.: Медицина; 2000; т. 1: 412.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Samoilovich E.O.,Yermalovich M.A., Semeiko G.V, Svirchevskaya E.I., Rimzha M.I., Titov L.P. Autbreak of measles in Belarus.Euro Surv. 2006, 11(7): EO60727.3.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Velicko I., Muller L.L., Pebody R., Gergonne B., Aidyralieva Ch., Kosttiuchenko N. et.al. Natiowide measles epidemic in Ukraine: the effect of low vaccine effectiveness. Vaccine. 2008; 26: 6980-5.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Update on measles in the European Region.http://www.euro.who. int/en/what-we-do/health-topics/disease-prevention/ vaccines-and-immunization/publications/who-epidemiological-briefs/ who-epidemiological-brief-18-measles-outbreaks,-member-state-responses,-measles-exportation-to-the-americas-region,-afp-surveillance-and-the-polio-outbreak-in-china</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Dietz V., Rota J., Izurieta H., Carrasco P., Bellini W.J. The laboratory confirmation of suspected measles cases in setting of low measles transmission: conclusions from the experience in the American. Bull. World Health Organ. 2004; 82 (11): 852-7.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Мамаева Т.А., Липская Г.Ю., Наумова М.А., Шульга С.В., Mulders M., Featherstoune D.A. Особенности лабораторной диагностики кори у больных с разным прививочным анамнезом. Вопросы вирусологии. 2012; 5: 21-6</mixed-citation></ref></ref-list></back></article>
